{"protocolSection":{"identificationModule":{"nctId":"NCT04856085","orgStudyIdInfo":{"id":"VIR-2218-1006"},"organization":{"fullName":"Vir Biotechnology, Inc.","class":"INDUSTRY"},"briefTitle":"Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection","officialTitle":"A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Containing VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection","acronym":"MARCH"},"statusModule":{"statusVerifiedDate":"2025-10","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2021-07-11","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-03","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-03","type":"ESTIMATED"},"studyFirstSubmitDate":"2021-04-21","studyFirstSubmitQcDate":"2021-04-21","studyFirstPostDateStruct":{"date":"2021-04-22","type":"ACTUAL"},"lastUpdateSubmitDate":"2025-10-17","lastUpdatePostDateStruct":{"date":"2025-10-21","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Vir Biotechnology, Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":true},"descriptionModule":{"briefSummary":"This is a phase 2 study in which participants with chronic hepatitis B virus (HBV) infection will receive VIR-2218, VIR-3434 and/or PEG-IFNα and be assessed for safety, tolerability, and efficacy"},"conditionsModule":{"conditions":["Hepatitis B, Chronic"],"keywords":["Hepatitis B Virus","Chronic Hepatitis B","HBV","Hepatitis"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"NON_RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":244,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Cohort 1a (VIR-2218 + VIR-3434)","type":"EXPERIMENTAL","description":"Participants will receive multiple lead-in doses of VIR-2218, then combination therapy with VIR-2218 + VIR-3434 for 20 weeks total","interventionNames":["Drug: VIR-2218","Drug: VIR-3434"]},{"label":"Cohort 2a (VIR-2218 + VIR-3434)","type":"EXPERIMENTAL","description":"Participants will receive multiple lead-in doses of VIR-2218, then combination therapy with VIR-2218 + VIR-3434 for 20 weeks total","interventionNames":["Drug: VIR-2218","Drug: VIR-3434"]},{"label":"Cohort 3a (VIR-2218 + VIR-3434)","type":"EXPERIMENTAL","description":"Participants will receive multiple doses of VIR-2218 + VIR-3434 for 4 weeks","interventionNames":["Drug: VIR-2218","Drug: VIR-3434"]},{"label":"Cohort 4a (VIR-2218 + VIR-3434)","type":"EXPERIMENTAL","description":"Participants will receive multiple doses of VIR-2218 + VIR-3434 for 4 weeks","interventionNames":["Drug: VIR-2218","Drug: VIR-3434"]},{"label":"Cohort 5a (VIR-2218 + VIR-3434)","type":"EXPERIMENTAL","description":"Participants will receive multiple doses of VIR-2218 + VIR-3434 for 11 weeks","interventionNames":["Drug: VIR-2218","Drug: VIR-3434"]},{"label":"Cohort 6a (VIR-2218 + VIR-3434)","type":"EXPERIMENTAL","description":"Participants will receive multiple doses of VIR-2218 + VIR-3434 for 11 weeks","interventionNames":["Drug: VIR-2218","Drug: VIR-3434"]},{"label":"Cohort 7a (VIR-2218 + VIR-3434)","type":"EXPERIMENTAL","description":"Participants will receive multiple doses of VIR-2218 + VIR-3434 for 44 weeks","interventionNames":["Drug: VIR-2218","Drug: VIR-3434"]},{"label":"Cohort 8a (VIR-2218 + VIR-3434)","type":"EXPERIMENTAL","description":"Participants will receive multiple doses of VIR-2218 + VIR-3434 for 20 weeks","interventionNames":["Drug: VIR-2218","Drug: VIR-3434"]},{"label":"Cohort 1b (VIR-3434)","type":"EXPERIMENTAL","description":"Participants will receive multiple doses of VIR-3434 for 44 weeks","interventionNames":["Drug: VIR-3434"]},{"label":"Cohort 2b (VIR-3434)","type":"EXPERIMENTAL","description":"Participants will receive multiple doses of VIR-3434 for 20 weeks","interventionNames":["Drug: VIR-3434"]},{"label":"Cohort 1c (VIR-2218 + VIR-3434 + PEG-IFNα)","type":"EXPERIMENTAL","description":"Participants will receive multiple doses of VIR-2218 + VIR-3434 + PEG-IFNα for 24 weeks","interventionNames":["Drug: VIR-2218","Drug: VIR-3434","Drug: PEG-IFNα"]},{"label":"Cohort 2c (VIR-2218 + VIR-3434 + PEG-IFNα)","type":"EXPERIMENTAL","description":"Participants will receive multiple doses of VIR-2218 + VIR-3434 + PEG-IFNα for 48 weeks","interventionNames":["Drug: VIR-2218","Drug: VIR-3434","Drug: PEG-IFNα"]},{"label":"Cohort 1d (VIR-3434 + PEG-IFNα)","type":"EXPERIMENTAL","description":"Participants will receive multiple doses of VIR-3434 + PEG-IFNα for 48 weeks","interventionNames":["Drug: VIR-3434","Drug: PEG-IFNα"]}],"interventions":[{"type":"DRUG","name":"VIR-2218","description":"VIR-2218 given by subcutaneous injection","armGroupLabels":["Cohort 1a (VIR-2218 + VIR-3434)","Cohort 1c (VIR-2218 + VIR-3434 + PEG-IFNα)","Cohort 2a (VIR-2218 + VIR-3434)","Cohort 2c (VIR-2218 + VIR-3434 + PEG-IFNα)","Cohort 3a (VIR-2218 + VIR-3434)","Cohort 4a (VIR-2218 + VIR-3434)","Cohort 5a (VIR-2218 + VIR-3434)","Cohort 6a (VIR-2218 + VIR-3434)","Cohort 7a (VIR-2218 + VIR-3434)","Cohort 8a (VIR-2218 + VIR-3434)"],"otherNames":["Elebsiran"]},{"type":"DRUG","name":"VIR-3434","description":"VIR-3434 given by subcutaneous injection","armGroupLabels":["Cohort 1a (VIR-2218 + VIR-3434)","Cohort 1b (VIR-3434)","Cohort 1c (VIR-2218 + VIR-3434 + PEG-IFNα)","Cohort 1d (VIR-3434 + PEG-IFNα)","Cohort 2a (VIR-2218 + VIR-3434)","Cohort 2b (VIR-3434)","Cohort 2c (VIR-2218 + VIR-3434 + PEG-IFNα)","Cohort 3a (VIR-2218 + VIR-3434)","Cohort 4a (VIR-2218 + VIR-3434)","Cohort 5a (VIR-2218 + VIR-3434)","Cohort 6a (VIR-2218 + VIR-3434)","Cohort 7a (VIR-2218 + VIR-3434)","Cohort 8a (VIR-2218 + VIR-3434)"],"otherNames":["Tobevibart"]},{"type":"DRUG","name":"PEG-IFNα","description":"PEG-IFNα given by subcutaneous injection","armGroupLabels":["Cohort 1c (VIR-2218 + VIR-3434 + PEG-IFNα)","Cohort 1d (VIR-3434 + PEG-IFNα)","Cohort 2c (VIR-2218 + VIR-3434 + PEG-IFNα)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Proportion of participants with treatment-emergent adverse events (TEAEs)","timeFrame":"Up to 72 weeks"},{"measure":"Proportion of participants with serious adverse events (SAEs)","timeFrame":"Up to 72 weeks"},{"measure":"Proportion of participants with hepatitis B surface antigen (HBsAg) loss (defined as undetectable HBsAg) at end of treatment","timeFrame":"Up to 48 weeks"},{"measure":"Proportion of participants with HBsAg loss (defined as undetectable HBsAg) at 24 weeks post-end of treatment","timeFrame":"Up to 72 weeks"}],"secondaryOutcomes":[{"measure":"Absolute serum HBsAg and change from baseline across all timepoints in the study","timeFrame":"Up to 110 weeks"},{"measure":"Nadir and maximum reduction of serum HBsAg from baseline","timeFrame":"Up to 110 weeks"},{"measure":"Proportion of participants achieving sustained suppression of HBV DNA (< lower limit of quantification (LLOQ) for >= 24 weeks after discontinuation of all treatment, including NRTIs)","timeFrame":"Up to 110 weeks"},{"measure":"For hepatitis B e-antigen (HBeAg)-positive participants: Proportion of participants with HBeAg loss (undetectable HBeAg) and/or anti-HBe seroconversion at any timepoint","timeFrame":"Up to 110 weeks"},{"measure":"For HBeAg-positive participants: Time to HBeAg loss (undetectable HBeAg) and/or anti-HBe seroconversion","timeFrame":"Up to 110 weeks"},{"measure":"Cmax","timeFrame":"Up to 110 weeks"},{"measure":"AUClast","timeFrame":"Up to 110 weeks"},{"measure":"t1/2","timeFrame":"Up to 110 weeks"},{"measure":"CL/F","timeFrame":"Up to 110 weeks"},{"measure":"Number of participants with incidence and titers of anti-drug antibody (ADA) (if applicable) to VIR-3434","timeFrame":"Up to 110 weeks"},{"measure":"Proportion of participants meeting criteria for nucleotide reverse transcriptase inhibitors (NRTI) discontinuation","timeFrame":"Up to 60 weeks"},{"measure":"Proportion of participants meeting criteria for NRTI retreatment","timeFrame":"Up to 110 weeks"},{"measure":"Proportion of participants achieving undetectable HBsAg and sustained suppression of HBV DNA [below the LLOQ, target not detected (TND)] >/= 24 weeks after discontinuation of all treatment, including NRTIs","timeFrame":"Up to 110 weeks"},{"measure":"Proportion of participants with serum HBsAg < 10 IU/mL at end of treatment","timeFrame":"Up to 48 weeks"},{"measure":"Proportion of participants with serum HBsAg < 10 IU/mL at 24 weeks post-end of treatment","description":"48 weeks treatment + 24 weeks post-end of treatment","timeFrame":"Up to 72 weeks"},{"measure":"Proportion of participants with anti-HBs seroconversion","timeFrame":"Up to 110 weeks"},{"measure":"Time to achieve nadir of serum HBsAg","timeFrame":"Up to 110 weeks"},{"measure":"Time to achieve serum HBsAg loss","timeFrame":"Up to 110 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female ages 18 - \\<66 years\n* Chronic HBV infection for \\>/= 6 months\n* On NRTI therapy for \\>/= 2 months at the time of screening\n\nExclusion Criteria:\n\n* Any clinically significant chronic or acute medical condition that makes the participant unsuitable for participation\n* Significant fibrosis or cirrhosis\n* History or evidence of drug or alcohol abuse\n* History of chronic liver disease from any cause other than chronic HBV infection\n* History of hepatic decompensation\n* History of anaphylaxis\n* History of allergic reactions, hypersensitivity, or intolerance to monoclonal antibodies, antibody fragments, or any excipients of VIR-3434\n* History of immune complex disease\n* History of known contraindication to any interferon product","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"Investigative Site","city":"San Francisco","state":"California","zip":"94143","country":"United States","geoPoint":{"lat":37.77493,"lon":-122.41942}},{"facility":"Investigative Site","city":"Miami","state":"Florida","zip":"33136","country":"United States","geoPoint":{"lat":25.77427,"lon":-80.19366}},{"facility":"Investigative Site","city":"Orlando","state":"Florida","zip":"32803","country":"United States","geoPoint":{"lat":28.53834,"lon":-81.37924}},{"facility":"Investigative Site","city":"Baltimore","state":"Maryland","zip":"21218","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"Investigative Site","city":"Hillsborough","state":"New Jersey","zip":"08844","country":"United States","geoPoint":{"lat":40.4776,"lon":-74.62682}},{"facility":"Investigative Site","city":"Toronto","zip":"2C4","country":"Canada","geoPoint":{"lat":43.70643,"lon":-79.39864}},{"facility":"Investigative Site","city":"Toronto","zip":"3M1","country":"Canada","geoPoint":{"lat":43.70643,"lon":-79.39864}},{"facility":"Investigative Site","city":"Vancouver","zip":"2C7","country":"Canada","geoPoint":{"lat":49.24966,"lon":-123.11934}},{"facility":"Investigative Site","city":"Frankfurt","zip":"60590","country":"Germany","geoPoint":{"lat":49.68333,"lon":10.53333}},{"facility":"Investigative Site","city":"Hanover","zip":"30625","country":"Germany","geoPoint":{"lat":52.37052,"lon":9.73322}},{"facility":"Investigative Site","city":"Mannheim","zip":"68167","country":"Germany","geoPoint":{"lat":49.4891,"lon":8.46694}},{"facility":"Investigative Site","city":"Hong Kong","state":"Shatin","country":"Hong Kong","geoPoint":{"lat":22.27832,"lon":114.17469}},{"facility":"Investigative Site","city":"Hong Kong","state":"Tai Po District","country":"Hong Kong"},{"facility":"Investigative Site","city":"Hong Kong","country":"Hong Kong","geoPoint":{"lat":22.27832,"lon":114.17469}},{"facility":"Investigative Site","city":"Kuala Lumpur","zip":"59100","country":"Malaysia","geoPoint":{"lat":3.1412,"lon":101.68653}},{"facility":"Investigative Site","city":"Chisinau","zip":"MD 2025","country":"Moldova","geoPoint":{"lat":47.00902,"lon":28.85938}},{"facility":"Investigative Site","city":"Auckland","zip":"1010","country":"New Zealand","geoPoint":{"lat":-36.84853,"lon":174.76349}},{"facility":"Investigative Site","city":"Auckland","zip":"2025","country":"New Zealand","geoPoint":{"lat":-36.84853,"lon":174.76349}},{"facility":"Investigative Site","city":"Hamilton","zip":"3204","country":"New Zealand","geoPoint":{"lat":-37.78333,"lon":175.28333}},{"facility":"Investigative Site","city":"Tauranga","zip":"3110","country":"New Zealand","geoPoint":{"lat":-37.68611,"lon":176.16667}},{"facility":"Investigative Site","city":"Wellington","zip":"6021","country":"New Zealand","geoPoint":{"lat":-41.28664,"lon":174.77557}},{"facility":"Investigative Site","city":"Bucharest","zip":"021105","country":"Romania","geoPoint":{"lat":44.43225,"lon":26.10626}},{"facility":"Investigative Site","city":"Busan","zip":"49421","country":"South Korea","geoPoint":{"lat":35.10168,"lon":129.03004}},{"facility":"Investigative Site","city":"Seoul","zip":"03080","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Investigative Site","city":"Seoul","zip":"05505","country":"South Korea","geoPoint":{"lat":37.566,"lon":126.9784}},{"facility":"Investigative Site","city":"Yangsan","zip":"50612","country":"South Korea","geoPoint":{"lat":35.34199,"lon":129.03358}},{"facility":"Investigative Site","city":"Chiayi City","zip":"60041","country":"Taiwan","geoPoint":{"lat":23.47917,"lon":120.44889}},{"facility":"Investigative Site","city":"Kaohsiung City","zip":"80756","country":"Taiwan","geoPoint":{"lat":22.61626,"lon":120.31333}},{"facility":"Investigative Site","city":"Kaohsiung City","zip":"83301","country":"Taiwan","geoPoint":{"lat":22.61626,"lon":120.31333}},{"facility":"Investigative Site","city":"Taichung","zip":"40705","country":"Taiwan","geoPoint":{"lat":24.1469,"lon":120.6839}},{"facility":"Investigative Site","city":"Taipei","zip":"100","country":"Taiwan","geoPoint":{"lat":25.05306,"lon":121.52639}},{"facility":"Investigative Site","city":"Taoyuan","zip":"33305","country":"Taiwan","geoPoint":{"lat":24.99368,"lon":121.29696}},{"facility":"Investigative Site","city":"Kyiv","zip":"01135","country":"Ukraine","geoPoint":{"lat":50.45466,"lon":30.5238}},{"facility":"Investigative Site","city":"Birmingham","zip":"B15 2TH","country":"United Kingdom","geoPoint":{"lat":52.48142,"lon":-1.89983}},{"facility":"Investigative Site","city":"London","zip":"E11FR","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"Investigative Site","city":"London","zip":"SE5 9RS","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}},{"facility":"Investigative Site","city":"Manchester","zip":"M8 5RB","country":"United Kingdom","geoPoint":{"lat":53.48095,"lon":-2.23743}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D019694","term":"Hepatitis B, Chronic"},{"id":"D006509","term":"Hepatitis B"},{"id":"D006505","term":"Hepatitis"}],"ancestors":[{"id":"D000086982","term":"Blood-Borne Infections"},{"id":"D003141","term":"Communicable Diseases"},{"id":"D007239","term":"Infections"},{"id":"D018347","term":"Hepadnaviridae Infections"},{"id":"D004266","term":"DNA Virus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D006525","term":"Hepatitis, Viral, Human"},{"id":"D006521","term":"Hepatitis, Chronic"},{"id":"D008107","term":"Liver Diseases"},{"id":"D004066","term":"Digestive System Diseases"},{"id":"D002908","term":"Chronic Disease"},{"id":"D020969","term":"Disease Attributes"},{"id":"D010335","term":"Pathologic Processes"},{"id":"D013568","term":"Pathological Conditions, Signs and Symptoms"}]}},"hasResults":false}